H&R GmbH & Co. KGaA confirms business figures for the first half of 2022

• Operating result (EBITDA) of € 72.8 million almost at very good level of previous year
• Significantly accelerated development during the year with earnings contribution of € 47.6 million in Q2 2022
• Full-year result expected to exceed € 100.0 million threshold

Salzbergen, Germany, August 15, 2022. H&R GmbH & Co. KGaA (abbreviated to H&R KGaA; ISIN DE000A2E4T77) achieved consolidated operating earnings (EBITDA - consolidated profit before income taxes, other finance income and expenses, and amortization, depreciation, and impairment losses and reversals of impairment losses on intangible assets and property, plant, and equipment) of EUR 72.8 million at the end of the first half of 2022 (H1 2021: EUR 74.4 million). EBIT amounted to EUR 46.2 million (first half of 2021: EUR 49.1 million). Consolidated net income attributable to shareholders closed at EUR 29.7 million (H1 2021: EUR 31.0 million). Thus, H&R KGaA generated earnings per share of EUR 0.80. Due to raw material prices, sales increased strongly in the first half of 2022 and reached revenues of EUR 805.8 million (H1 2021: EUR 558.4 million).

Overview of key figures:

For the full year, H&R KGaA currently expects to achieve an operating result above the threshold of EUR 100.0 million. Should visibility increase significantly in the coming months, we will further specify our expectations.

For detailed statements on the current and further business and earnings development, the company refers to the half-year report as of June 30, 2022, published today, which is available for download at in the "Publications" section of H&R KGaA.

Contact information:

H&R GmbH & Co. KGaA, Head of Investor Relations/Communications, Ties Kaiser

Neuenkirchener Strasse 8, 48499 Salzbergen

Tel.: 1, Fax: 0

e-mail: ;

H&R GmbH & Co. KGaA:

H&R KGaA is a specialty-chemicals company listed on the Frankfurt Stock Exchange's Prime Standard segment. It develops and manufactures crude-oil-based chemical and pharmaceutical specialty products and produces high-precision plastic parts.

Forward-looking statements and forecasts:

This press release contains forward-looking statements. The statements are based on the current estimates and forecasts by the Executive Board and the information available to the Board at this time. These forward-looking statements do not provide any warranty for the future developments and results contained therein. The future developments and results are dependent on a number of factors; they entail various risks and contingencies and are based on assumptions which could prove to be incorrect. We do not assume any responsibility for updating the forward-looking statements contained in this press release.